| Literature DB >> 31528797 |
Hadil M Elbardisy1,2, Christopher W Foster1, Jack Marron1,1, Ryan E Mewis1, Oliver B Sutcliffe1,1, Tarek S Belal3, Wael Talaat2, Hoda G Daabees2, Craig E Banks1.
Abstract
The emergence of a new class of novel psychoactive substances, N-benzyl-substituted phenethylamine derivatives so-called "NBOMes" or "Smiles", in the recreational drug market has forced the development of new sensitive analytical methodologies for their detection and quantitation. NBOMes' hallucinogenic effects mimic those of the illegal psychedelic drug lysergic acid diethylamide (LSD) and are typically sold as LSD on blotter papers, resulting in a remarkable number of fatalities worldwide. In this article, four halide derivatives of NBOMe, namely, 2-(4-fluoro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, and 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine, were detected and quantified simultaneously using a high-performance liquid chromatographic method, and two detection systems were compared: photodiode array detection (detection system I) and amperometric detection via a commercially available impinging jet flow-cell system incorporating embedded graphite screen-printed macroelectrodes (detection system II). Under optimized experimental conditions, linear calibration plots were obtained in the concentration range of 10-300 and 20-300 μg mL-1, for detection systems I and II, respectively. Detection limit (limit of detection) values were between 4.6-6.7 and 9.7-18 μg mL-1, for detection systems I and II, respectively. Both detectors were employed for the analysis of the four NBOMe derivatives in the bulk form, in the presence of LSD and adulterants commonly found in street samples (e.g. paracetamol, caffeine, and benzocaine). Furthermore, the method was applied for the analysis of simulated blotter papers, and the obtained percentage recoveries were satisfactory, emphasizing its advantageous applicability for the routine analysis of NBOMes in forensic laboratories.Entities:
Year: 2019 PMID: 31528797 PMCID: PMC6740171 DOI: 10.1021/acsomega.9b01366
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Scheme 1Synthesis of 25F-, 25C-, 25B-, and 25I-NBOMe·HCl Derivatives (2a–d) from Their Corresponding Phenethylamine Hydrochlorides (1a–d),
Reagents and conditions: (i) 2-methoxybenzaldehyde/EtOH/room temperature (rt); (ii) NaBH4/EtOH/rt; (iii) HCl (3 M solution in cyclopentyl methyl ether).
(3) Chemical structure of illicit lysergic acid diethylamide (LSD).
Comparison of Previous Analytical Approaches for the Analysis of NBOMe Derivatives
| analytical method | target analytes | limit of detection (LOD) | limit of quantitation (LOQ) | linearity range | ref |
|---|---|---|---|---|---|
| LC–MS/MS | 25I-NBOMe | Δ | 25 pg mL–1 | 25–2000 pg mL–1 | ( |
| LC–MS/MS | 25C-, 25B-, 25I-NBOMe | Δ | 1 ng mL–1 | 1–100 ng mL–1 | ( |
| LC–MS/MS | 25C-, 25B-, 25I-, 25D-, 25H-NBOMe | 0.02–0.05 ng mL–1 | 0.08–0.1 ng mL–1 | 0.1–5.0 ng mL–1 | ( |
| LC–MS/MS | 25C-, 25B-, 25I-NBOMe | urine: 5–25 pg mL–1 | urine: 50 pg mL–1 | urine: 0.1–100 ng mL–1 | ( |
| hair: 3–5 pg mg–1 | hair: 6.25–12.5 pg mg–1 | hair: 0.025–2.5 ng mg–1 | |||
| LC–MS/MS | 25B-NBOMe | Δ | plasma: 0.1 mg L–1 | plasma:0.1–10 mg L–1 | ( |
| urine: 1 mg L–1 | urine: 1–200 mg L–1 | ||||
| LC–MS/MS | 25C-, 25B-, 25I-, 25D-, 25H-, 25T2-NBOMe | 0.005–0.01 ng mL–1 | 0.01–0.02 ng mL–1 | 0.01–20 ng mL–1 | ( |
| LC–MS/MS | 25I-, 25G-, 25B-, 25D-, 25H-NBOMe | 0.1 ng mL–1 | 1 ng mL–1 | 1–100 ng mL–1 | ( |
| LC–MS/MS | 25I-NBOMe | 10 pg mL–1 | 30 pg mL–1 | 30–2000 pg mL–1 | ( |
| LC–MS/MS | 25I-NBOMe | 0.09 ng mL–1 | 0.1 ng mL–1 | 0.1–0.5 ng mL–1 | ( |
| LC–MS/MS | 25C-, 25B-NBOMe | qualitative analysis | qualitative analysis | qualitative analysis | ( |
| LC–MS/MS | 25B-NBOMe | 10 pg mL–1 | 25 pg mL–1 | 25–2000 pg mL–1 | ( |
| UPLC–MS/MS | 25B-, 25I-NBOMe | 0.2 ng mL–1 | 0.5 ng mL–1 | 0.5–20 ng mL–1 | ( |
| UPLC–MS/MS | 25I-, 25C-, 25H-NBOMe | Δ | Δ | 1–500 ng mL–1 | ( |
| UPLC–MS/MS | 25B-NBOMe | 5.3 pg mL–1 | 15.9 pg mL–1 | 10–1000 pg mL–1 | ( |
| UPLC–MS/MS | 25C-NBOMe | 0.02 μg kg–1 | 0.08 μg kg–1 | 0.1–10 μg kg–1 | ( |
| GC–MS | 25I-NBOMe | qualitative analysis | qualitative analysis | qualitative analysis | ( |
| PSI-MS | 25C-, 25B-, 25I-NBOMe | qualitative analysis | qualitative analysis | qualitative analysis | ( |
| ATR-FTIR | 25C-, 25B-, 25I-NBOMe | qualitative analysis | qualitative analysis | qualitative analysis | ( |
| HPLC-DAD | 25C-, 25B-, 25I-NBOMe | 5 μg mL–1 | Δ | 20–330 μg mL–1 | ( |
| HPTLC | 25B-NBOMe | 7.12 μg per band | 21.56 μg per band | 19.18–115.00 μg per band | ( |
| HPTLC | 25C-NBOMe | 7.1 μg per band | 21.63 μg per band | 19.72–118.28 μg per band | ( |
| differential pulse voltammetry | 25B-, 25I-NBOMe | 0.011 and 0.004 mg mL–1 | 0.034 and 0.012 mg mL–1 | 0.01–0.08 mg mL–1 | ( |
| square wave voltammetry | 25H-NBOMe | 1.28 × 10–6 mol L–1 | 4.25 × 10–6 mol L–1 | 4.25 × 10–6–4.96 × 10–5 mol L–1 | ( |
| square wave voltammetry | 25C-, 25B-, 25I-NBOMe | 0.05–0.1 μmol L–1 | Δ | 0.2–340 μmol L–1 | ( |
| square wave voltammetry | 25C-, 25B-, 25I-NBOMe | 0.1–0.27 μmol L–1 | Δ | 1–555 μmol L–1 | ( |
| this work HPLC-DAD (detection system I) | 25F-, 25C-, 25B-, 25I-NBOMe | 4.56–6.65 μg mL–1 | 10 μg mL–1 | 10–300 μg mL–1 | |
| this work HPLC-AD (detection system II) | 9.65–17.98 μg mL–1 | 20 μg mL–1 | 20–300 μg mL–1 |
Δ: not disclosed; LC–MS/MS: liquid chromatography–tandem mass spectrometry; UPLC–MS/MS: ultraperformance liquid chromatography–tandem mass spectrometry; GC–MS: gas chromatography–mass spectrometry; PSI-MS: paper spray ionization-mass spectrometry; ATR-FTIR: attenuated total reflection-Fourier transform infrared spectroscopy; HPLC-DAD: high-performance liquid chromatography-photodiode array detection; HPTLC: high-performance thin-layer chromatography.
Figure 1Cyclic voltammograms of 100 μg mL–1 of each of 25F-NBOMe (2a), 25C-NBOMe (2b), 25B-NBOMe (2c), and 25I-NBOMe (2d) in a 0.04 M B–R buffer (pH 7.0) using SPEs. Scan rate: 50 mV s–1 vs Ag/AgCl reference electrode. (I) First NBOMes’ oxidation peak; (II) second NBOMes’ oxidation peak.
Summary of the Anodic Peak Potentials (Ep1 and Ep2) of NBOMe Derivatives (2a–d) Obtained Using SPEs vs Ag/AgCl
| peak
potential | ||
|---|---|---|
| NBOMe derivatives | ||
| 25F-NBOMe ( | +0.815 | +0.996 |
| 25C-NBOMe ( | +0.817 | +1.027 |
| 25B-NBOMe ( | +0.829 | +1.031 |
| 25I-NBOMe ( | +0.800 | +1.013 |
Scheme 2Electrochemical Oxidation Mechanism of NBOMe Halide Derivatives Previously Reported by Andrade et al.[9]
Summary of the Optimized Experimental Parameters Chosen for the Separation and Quantitation of NBOMe Derivatives
| studied experimental parameter | optimized parameter |
|---|---|
| analytical column | ACE 5 C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm) |
| mobile phase | isocratic (5 mM ammonium formate + 100 mM KCl:acetonitrile 70:30% v/v) |
| ionic strength of ammonium formate buffer | 5 mM |
| pH of the aqueous phase | pH 7 |
| linear velocity of the mobile phase | 2.5 mL min–1 |
| column temperature | 60 °C |
| applied potential for amperometric detection (AD) | +1.0 V |
| detection wavelength λ for photodiode array detection (DAD) | 205 nm |
Figure 2(A) Representative HPLC-DAD chromatogram of a solution containing 100 μg mL–1 of each of “F”: 25F-NBOMe (2a), “Cl”: 25C-NBOMe (2b), “Br”: 25B-NBOMe (2c), and “I”: 25I-NBOMe (2d). (B) Representative HPLC-AD amperogram of a solution containing 100 μg mL–1 of each of F: 25F-NBOMe (2a), Cl: 25C-NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). Experimental parameters include ACE C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm), mobile phase: [5 mM ammonium formate + 100 mM KCl (pH 7.0): acetonitrile 70:30 (v/v)], flow rate: 2.5 mL min–1, column temperature: 60 °C, detector wavelength (UV): 205 nm, and potential: +1.0 V.
Summary of HPLC-DAD (Detection System I) Validation Data for the Quantification of NBOMe Halide Derivatives (2a–d) Using ACE C18-AR Column (150 × 4.6 mm2 i.d., Particle Size: 5 μm), Mobile Phase: [5 mM Ammonium Formate + 100 mM KCl (pH 7.0): Acetonitrile 70:30% (v/v)], Flow Rate: 2.5 mL min–1, Column Temperature: 60 °C, and Detector Wavelength (UV): 205 nm
| drug
of abuse | ||||
|---|---|---|---|---|
| parameters | 25F-NBOMe ( | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( |
| 0.999 | 0.999 | 0.999 | 0.999 | |
| –13.52 | –29.79 | –41.17 | –34.88 | |
| 9.08 | 16.38 | 23.12 | 15.58 | |
| LOD (μg mL–1) | 4.56 | 5.90 | 5.14 | 6.65 |
| Precision (% RSD, | ||||
| 10 (μg mL–1) | 0.70 | 0.98 | 1.14 | 0.51 |
| 20 (μg mL–1) | 0.58 | 1.84 | 1.78 | 0.01 |
| 50 (μg mL–1) | 1.26 | 1.42 | 1.00 | 0.28 |
| 100 (μg mL–1) | 1.08 | 0.76 | 0.65 | 0.98 |
| 150 (μg mL–1) | 0.49 | 0.31 | 0.38 | 0.82 |
| 200 (μg mL–1) | 0.93 | 0.30 | 0.36 | 0.79 |
| 300 (μg mL–1) | 0.27 | 0.40 | 0.47 | 0.58 |
| System Suitability Parameters | ||||
| 3.83 ± 0.02 | 5.96 ± 0.02 | 7.01 ± 0.03 | 9.45 ± 0.05 | |
| RRT | 0.41 | 0.63 | 0.74 | 1 |
| 5.18 | 8.61 | 10.31 | 14.24 | |
| 8000 | 8629 | 8967 | 8670 | |
| HETP (m) | 1.88 × 10–5 | 1.74 × 10–5 | 1.67 × 10–5 | 1.73 × 10–5 |
| 9.97 | 3.82 | 6.95 | ||
| 0.85 | 0.82 | 0.85 | 0.94 | |
| α | 1.66 | 1.20 | 1.38 | |
r2: coefficient of regression.
y = 9.08x – 13.52.
y = 16.38x – 29.79.
y = 23.12x – 41.17.
y = 15.58x – 34.88.
a: intercept of the regression line of the calibration curve.
b: slope of the regression line of the calibration curve.
LOD: limit of detection using the formula (3S)/b.
tR: retention time in minutes for drugs eluted from the chromatographic column (Detection System I).
RRT: relative retention time (determined with respect to 25I-NBOMe, 2d, retention time obtained from Detection System I).
k′: capacity factor.
N: number of theoretical plates expressed in plates per meter.
HETP: height equivalent to the theoretical plate expressed in meter.
Rs: resolution between two successive eluted peaks.
As: asymmetry factor.
α: relative retention factor.
Summary of HPLC-AD (Detection System II) Validation Data for the Quantification of NBOMe Halide Derivatives (2a–d) Using ACE C18-AR Column (150 × 4.6 mm2 i.d., Particle Size: 5 μm), Mobile Phase: [5 mM Ammonium Formate + 100 mM KCl (pH 7.0): Acetonitrile 70:30% (v/v)], Flow Rate: 2.5 mL min–1, Column Temperature: 60 °C, and Potential: +1.0 V
| drug
of abuse | ||||
|---|---|---|---|---|
| parameters | 25F-NBOMe ( | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( |
| 0.997 | 0.998 | 0.999 | 0.999 | |
| 14.57 × 10–2 | 8.93 × 10–2 | 8.52 × 10–2 | 4.62 × 10–2 | |
| 5.70 × 10–3 | 2.85 × 10–3 | 3.68 × 10–3 | 2.37 × 10–3 | |
| LOD (μg mL–1) | 17.98 | 16.52 | 9.65 | 10.54 |
| Precision (% RSD, | ||||
| 20 (μg mL–1) | 0.74 | 0.45 | 1.84 | 0.83 |
| 50 (μg mL–1) | 0.57 | 0.84 | 0.97 | 1.54 |
| 100 (μg mL–1) | 0.79 | 0.77 | 0.69 | 1.12 |
| 150 (μg mL–1) | 0.87 | 0.63 | 0.97 | 0.07 |
| 200 (μg mL–1) | 0.72 | 0.24 | 0.27 | 0.97 |
| 300 (μg mL–1) | 0.32 | 0.95 | 0.53 | 0.63 |
| System Suitability Parameters | ||||
| 3.84 ± 0.02 | 5.97 ± 0.02 | 7.02 ± 0.03 | 9.46 ± 0.05 | |
| RRT | 0.41 | 0.63 | 0.74 | 1 |
r2: coefficient of regression.
y = 0.0057x + 0.1457.
y = 0.0029x + 0.0893.
y = 0.0037x + 0.085.
y = 0.0024x + 0.0462.
a: intercept of regression line of the calibration curve.
b: slope of regression line of the calibration curve.
LOD: limit of detection using the formula (3S)/b.
tR: retention time in minutes for drugs eluting from the flow cell Detection System II).
RRT: relative retention time (determined with respect to 25I-NBOMe, 2d, retention time obtained from Detection System II).
Figure 3(A) Representative HPLC-DAD chromatogram of a solution containing 100 μg mL–1 of each of LSD, F: 25F-NBOMe (2a), Cl: 25C-NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). (B) Representative HPLC-AD amperogram of a solution containing 100 μg mL–1 of each of LSD, F: 25F-NBOMe (2a), Cl: 25C-NBOMe (2b), Br: 25B-NBOMe (2c), and I: 25I-NBOMe (2d). Experimental parameters include ACE C18-AR column (150 × 4.6 mm2 i.d., particle size: 5 μm), mobile phase: [5 mM ammonium formate + 100 mM KCl (pH 7.0): acetonitrile 70:30% (v/v)], flow rate: 2.5 mL min–1, column temperature: 60 °C, detector wavelength (UV): 205 nm, and potential: +1.0 V.
Comparison between Quantitative Data Obtained by HPLC-DAD (Detection System I) and HPLC-AD (Detection System II) for the Analysis of NBOMe Derivatives (2a–d) in Simulated Blotter Papers
| | detection system I (HPLC-DAD) | detection system II (HPLC-AD) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| detection
system | drug | ||||||||
| sample | parameter | LSD | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( | LSD | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( |
| 2.8 ± 0 | 6.0 ± 0.1 | 7.0 ± 0 | 9.5 ± 0.1 | 2.8 ± 0 | 6.0 ± 0.1 | 7.0 ± 0 | 9.5 ± 0.1 | ||
| blotter paper I | mean % | + | – | – | 99 ± 0.8 | + | – | – | 100 ± 2.7 |
| RSD % | + | – | – | 1 | + | – | – | 3 | |
| + | – | – | –1 | + | – | – | 0 | ||
| blotter paper II | mean % | + | 100 ± 0.1 | – | 100 ± 0.1 | + | 101 ± 0.5 | – | 100 ± 1.4 |
| RSD % | + | 1 × 10–1 | – | 1 × 10–1 | + | 1 | – | 1 | |
| + | 0 | – | 0 | + | 1 | – | 0 | ||
| blotter paper III | mean % | – | – | 99 ± 1.5 | – | – | – | 99 ± 2.2 | – |
| RSD % | – | – | 2 | – | – | – | 2 | – | |
| – | – | –1 | – | – | – | –1 | – | ||
Mean % recovery ± standard deviation (SD) of three determinations for each drug detected in each blotter paper.
% relative standard deviation of three determinations for each drug detected in each blotter paper.
% relative error; (+) = present in the blotter paper sample; (−) absent from the blotter paper sample.
Comparison between Standard Addition Statistical Analysis Obtained by HPLC-DAD (Detection System I) and HPLC-AD (Detection System II) for the Quantitation of NBOMe Derivatives (2a–d) in Simulated Blotter Papers
| | detection system I (HPLC-DAD) | detection system II (HPLC-AD) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| detection
system | drug | ||||||||
| sample | parameter | LSD | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( | LSD | 25C-NBOMe ( | 25B-NBOMe ( | 25I-NBOMe ( |
| 2.8 ± 0 | 6.0 ± 0.1 | 7.0 ± 0 | 9.5 ± 0.1 | 2.8 ± 0 | 6.0 ± 0.1 | 7.0 ± 0 | 9.5± 0.1 | ||
| blotter paper I | mean % | + | – | – | 102 ± 1.0 | + | – | – | 100 ± 0.3 |
| RSD % | + | – | – | 1 | + | – | – | 3 × 10–1 | |
| + | – | – | 2 | + | – | – | 0 | ||
| blotter paper II | mean % | + | 102 ± 0.5 | – | 98 ± 1 | + | 98 ± 1.5 | – | 99 ± 2.1 |
| RSD % | + | 1 | – | 1 | + | 2 | – | 2 | |
| + | 2 | – | –2 | + | –2 | – | –1 | ||
| blotter paper III | mean % | – | – | 101 ± 1.7 | – | – | – | 99 ± 2 | – |
| RSD % | – | – | 2 | – | – | – | 2 | – | |
| – | – | 1 | – | – | – | –1 | – | ||
Mean % recovery ± SD of three determinations for each drug detected in each blotter paper.
% relative standard deviation of three determinations for each drug detected in each blotter paper.
% relative error; (+) = present in the blotter paper sample; (−) absent from the blotter paper sample.